Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. Since all three domestic clinical trials of the company's simeglutide injection (glycemic control indications, weight loss indications) have been completed, the simeglutide injection (weight loss indication) has cooperated with Sansheng Mandi and the joint application CDE has been accepted. Recently, after friendly negotiations, the company and Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. (hereinafter referred to as “Sansheng Mandi”) reached an agreement and signed the “Simeglutide Injection - Blood Sugar Control Cooperation Agreement for Adult Type 2 Diabetics” and “Commissioned Production and Supply Agreement”. The two sides reached cooperation on the development, registration, production and commercialization of simeglutide injections (glycemic control indications) in the Chinese region (mainland China, Hong Kong, Macau, excluding Taiwan).

Zhitongcaijing · 1d ago
Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. Since all three domestic clinical trials of the company's simeglutide injection (glycemic control indications, weight loss indications) have been completed, the simeglutide injection (weight loss indication) has cooperated with Sansheng Mandi and the joint application CDE has been accepted. Recently, after friendly negotiations, the company and Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd. (hereinafter referred to as “Sansheng Mandi”) reached an agreement and signed the “Simeglutide Injection - Blood Sugar Control Cooperation Agreement for Adult Type 2 Diabetics” and “Commissioned Production and Supply Agreement”. The two sides reached cooperation on the development, registration, production and commercialization of simeglutide injections (glycemic control indications) in the Chinese region (mainland China, Hong Kong, Macau, excluding Taiwan).